Literature DB >> 30601

Biotransformation of methyl 5-cyclopropylcarbonyl-2-benzimidazolecarbamate (ciclobendazole) in rats and dogs.

B C Mayo, R R Brodie, L F Chasseaud, D R Hawkins.   

Abstract

A major metabolite of ciclobendazole (methyl 5-cyclopropylcarbonyl-2-benzimidazolecarbamate) excreted in the urine, bile, and feces of rats was methyl 5-cyclopropylcarbonyl-6-hydroxy-benzimidazolecarbamate, established by comparison of the proton magnetic resonance and mass spectra with that of the authentic compound. This compound represented 8.2% and 7.1% of the dose, respectively, in extracts of 24-hr urine and 48-hr feces samples of rats, but was only a minor metabolite in dog urine (1% of the dose). The unchanged drug was only detected in dog feces, the major route of excretion of radioactivity in the dog. 5-Cyclopropylcarbonyl-2-amino-benzimidazole was present in rat urine (2.5% of the dose). A major metabolite in dog bile was probably 5-cyclopropylcarbinol-2-aminobenzimidazole, formed by loss of the methoxycarbonyl group and reduction of the carbonyl function in the 5-position.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 30601      PMCID: PMC8333785     

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Some aspects of the teratogenicity of veterinary drugs.

Authors:  P Delatour
Journal:  Vet Res Commun       Date:  1983-12       Impact factor: 2.459

2.  In vivo metabolism of the anti-inflammatory agent 2-(5-ethylpyridin-2-yl)benzimidazole.

Authors:  O Caputo; G Grosa; M Ceruti; F Viola; F Rocco
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

3.  Identification of biliary metabolites of mebendazole in the rat.

Authors:  R J Allan; T R Watson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

4.  The metabolic fate of 11-bromo[15-3H]vincamine in man.

Authors:  B C Mayo; S R Biggs; D R Hawkins; L F Chasseaud; A Darragh; F C Leaf
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.